Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the compensation committee of the company's board of directors granted eleven new employees options to purchase a total of 30,950 shares of the company's common stock at an exercise price per share of $32.98, which was the closing price on march 23, 2022, and restricted stock units to acquire a total of 15,475
RCUS Ratings Summary
RCUS Quant Ranking